The research, led by Prudhvi Thirumalaraju, Manoj Kumar Kanakasabapathy, and Hadi Shafiee of Brigham and Women’s Hospital and Harvard Medical School, together with collaborators at Weill Cornell Medicine, introduces a model called Cohort-AI. Rather than evaluating embryos one by one, Cohort-AI uses a machine learning framework known as multi-instance learning to assess an entire patient’s set of embryos simultaneously, predicting the cumulative live-birth outcome of the cohort and ranking each embryo by its relative contribution to that outcome. The approach mirrors the way embryologists reason: an embryo that looks average on its own might be the best option in a weak cohort, while a good-looking embryo might rank lower in a set full of excellent candidates.

The motivation for the work comes from an uncomfortable finding in recent literature. A previous evaluation of eight commercial AI algorithms for embryo ranking found that agreement between the algorithms and human embryologists was lower than expected, and in some cases the models disagreed with each other. Most strikingly, two of the commercial models produced rankings that were statistically indistinguishable from random chance. Even when the models were fine-tuned on center-specific data, the discrepancies persisted. The problem, the researchers argue, is a phenomenon known in machine learning as underspecification: when many different internal solutions can achieve similar overall accuracy, small variations in training—such as the random seed used to initialize the network’s weights—can produce large, unpredictable changes in individual decisions, even while headline performance metrics look stable.

To test whether a cohort-aware design could tame this instability, the team trained fifty replicate versions of both a conventional single-instance convolutional neural network and the new Cohort-AI model, differing only in their random initialization. All training used more than 10,000 Day-5 embryo images from 1,258 patients at Massachusetts General Hospital, captured with time-lapse incubators. A separate dataset of 648 embryos from 53 patients at Weill Cornell was held out entirely as an independent external test set, with no tuning or adaptation of any kind. The researchers then measured how consistently the fifty replicate models of each type ranked the same embryos for the same patients.

The results were stark. On the Massachusetts General Hospital test set of 92 patient cohorts, the replicate Cohort-AI models achieved an average Kendall’s W—a statistical measure of rank-order agreement ranging from zero, meaning no agreement, to one, meaning perfect agreement—of approximately 0.94. The single-instance models managed only about 0.36. On the external Cornell data, the pattern held: roughly 0.91 for Cohort-AI versus 0.34 for the conventional approach, with both differences highly statistically significant. In practical terms, the conventional models, trained identically except for a random starting point, frequently disagreed with themselves about which embryo was best, while the cohort-aware models produced nearly identical rankings across all fifty replicates.

Consistency translated directly into fewer dangerous mistakes. The team defined a critical error as a case in which a model ranked a degenerate, grade 1 embryo as the top choice even though a viable blastocyst of grade 3 or better was present in the same cohort. On the internal test set, single-instance models made such errors at an average rate of about 12.4 percent, with individual models ranging from roughly 4 to 22 percent. Cohort-AI cut that rate to about 2.3 percent. On the external Cornell data the gap widened further: about 17.3 percent for the conventional models versus 1.24 percent for Cohort-AI. Notably, the variance in error rates across replicate models also collapsed for the cohort-aware approach, and formal testing showed that this variance did not significantly increase when the model was applied to the unfamiliar Cornell data—evidence that the stability survived a genuine distribution shift between two different clinics and microscope models.

The study also probed what the model had actually learned. Using attention mechanisms—the component of the network that assigns weights to different inputs when forming a decision—the researchers found that Cohort-AI consistently concentrated its attention on embryos of higher morphological grade, as judged by the modified Gardner grading system used in clinics, and assigned the lowest attention to empty wells in the culture dish. Feature-space visualizations showed that replicate Cohort-AI models clustered tightly together in how they represented embryos from the same patient, whereas the conventional models diverged widely. The authors are careful to note that attention weights are treated as a descriptive weighting mechanism, not as causal proof of embryo importance, but the alignment with embryologist grading suggests the model’s comparative reasoning resembles human judgment rather than exploiting spurious shortcuts.

Perhaps most importantly for clinical credibility, the stability did not come at the cost of performance. In retrospective comparisons against historical clinical outcomes, Cohort-AI’s top-ranked embryos matched the embryos clinicians actually transferred 68.7 percent of the time at Massachusetts General Hospital, compared with 44.7 percent for the single-instance models, and the live-birth rate associated with those top selections was 44.8 percent versus 41.0 percent—both above the center’s baseline of 35.1 percent for the evaluated patients. At Cornell, Cohort-AI again showed higher transfer and live-birth rates with at least twice the consistency. When the analysis was restricted to cycles known to contain at least one successful live birth, the median Cohort-AI model produced 29 live births from about 35 transfers on the internal data, while the median conventional model produced only 16 from about 23 transfers. The lowest-performing Cohort-AI replicates performed comparably to the highest-performing conventional models, meaning clinicians would no longer need to gamble on which replicate they happened to deploy.

A single-patient case study crystallized why these differences matter. For one patient with three high-quality blastocysts, one moderate blastocyst, and two degenerate embryos, consensus among five embryologists was unambiguous. Yet 33 of the 50 conventional models ranked a degenerate embryo above a high-quality one, 31 ranked a high-quality embryo last, and seven—including the three models with the highest validation accuracy—placed a degenerate embryo first. Pairwise rank correlations among the conventional models averaged just 0.27, with some pairs producing exactly opposite orderings. All fifty Cohort-AI models, by contrast, ranked the high-quality embryos at the top and the degenerate ones at the bottom, with an average pairwise correlation of 0.99. The two embryos Cohort-AI consistently ranked highest were among those that had resulted in live births. The lesson, the authors argue, is that strong validation accuracy is an insufficient proxy for clinical reliability in ranking tasks.

The implications extend beyond embryology. The authors contend that embryo selection is inherently a comparative problem, not a binary classification, and that validation frameworks designed for diagnostic AI—where each sample has a clear ground truth—are poorly suited to it. They call for standardized benchmarks that measure not only accuracy but also ranking reproducibility, cross-site robustness, and behavior across software updates, noting that AI adoption in IVF has surged from roughly a quarter of clinics in 2022 to more than half in 2025 even as many clinicians report low confidence in interpreting these systems. The team is candid about limitations: the study is retrospective, the associations with live birth are correlational rather than causal, both centers used the same family of time-lapse incubators, and no blinded comparison against embryologist rankings was performed. Prospective, multi-center trials remain the necessary next step. But the central message is clear and potentially field-changing: for AI to become dependable infrastructure in IVF, rankings must remain predictable as data and software evolve—and building the comparison into the model itself, rather than leaving it out, appears to be a powerful way to get there.

Subject of Research: A multi-instance learning AI model for stable and reliable AI-assisted embryo selection in IVF

Article Title: Cohort-AI: A multi-instance learning approach for improved stability and reliability in AI-assisted embryo selection

Article References: Thirumalaraju, P., Kanakasabapathy, M. K., Kandula, H., Kandula, T., Katkuri, A. V. R., Cipriano, C., Malmsten, J. E., Zaninovic, N., Bormann, C. L., & Shafiee, H. (2026). Cohort-AI: A multi-instance learning approach for improved stability and reliability in AI-assisted embryo selection. Heliyon, 12(15), Article e45457. https://doi.org/10.1016/j.heliyon.2026.e45457

Image Credits: AI Generated

DOI: 10.1016/j.heliyon.2026.e45457

Keywords: in vitro fertilization, embryo selection, artificial intelligence, multi-instance learning, deep learning, reproductive medicine, Kendall's W, model stability, underspecification, attention mechanisms, clinical decision support, time-lapse imaging

The team, led by Aiyu Zhang and Dongmei Wang of the Reproductive Medicine Center at Yantaishan Hospital, together with colleagues from Qilu Medical University and Shandong Medical and Pharmaceutical University, assembled a retrospective cohort of 1,058 couples who underwent 1,419 complete IVF cycles. The data were drawn from patients treated in Yantai, in Shandong Province, and were divided chronologically: couples treated between 2019 and 2022 formed the development cohort on which the models were trained, while those treated in 2023 served as a temporal validation cohort. This design matters because a model that performs well only on the data it was trained on is of limited clinical value. Temporal validation, testing the model on patients treated in a later period, provides a stricter test of whether the model’s accuracy will hold up as patient populations, laboratory practices, and clinical protocols evolve over time.

From the patient records, the researchers extracted variables spanning three domains: baseline patient characteristics, clinical parameters collected during treatment, and detailed embryo data. They then built prediction models using eight different machine learning algorithms, a standard strategy in predictive modeling that allows investigators to compare how different learning approaches capture the structure of the data. The winner of this bake-off was a gradient boosting machine, an ensemble technique that builds a strong predictor by sequentially adding simple decision trees, each new tree trained to correct the errors of the combined model so far. Gradient boosting has become a workhorse of modern medical prediction because it handles nonlinear relationships and interactions between variables gracefully, often outperforming simpler methods such as logistic regression when the underlying biology is complex and multidimensional.

The final model, which the authors call CLBR-GBM, relied on just eight predictors, a deliberately parsimonious design that eases implementation in busy clinics. Its performance in the temporal validation cohort was strong across several complementary metrics. The area under the receiver operating characteristic curve, or AUROC, a measure of how well the model distinguishes couples who will achieve a live birth from those who will not, reached 0.851. The F1 score, which balances precision and recall, was 0.801. The Brier score, which penalizes both poor discrimination and poorly calibrated probabilities, was 0.155, with lower values indicating better performance. An additional metric, the ABscore, registered 0.848. Together these figures indicate that the model not only ranked patients correctly but also produced probability estimates that were reasonably well calibrated, a property that is essential when the output is meant to inform real decisions rather than merely satisfy statistical curiosity.

What sets this study apart from the crowded field of IVF prediction models is its second act: a systematic effort to convert prediction into actionable insight. The authors deployed a battery of causal inference techniques, including serial mediation analysis, diverse counterfactual explanations known by the acronym DiCE, double machine learning, and the T-learner approach. Each of these methods addresses the same fundamental problem from a different angle. Standard machine learning models learn associations, but an association between, say, body mass index and live birth does not by itself prove that changing one will change the other. Confounding factors, variables that influence both the predictor and the outcome, can create spurious relationships. Counterfactual explanation methods ask a subtly different question: for a specific patient, what is the smallest change in the input variables that would flip the model’s prediction across a decision threshold? Double machine learning, meanwhile, uses flexible machine learning models to adjust for confounders while estimating treatment effects, and the T-learner estimates effects separately within groups that received different levels of an exposure.

The causal analysis converged on a clear message. The primary pattern that shifted a couple’s predicted probability across the optimal decision threshold toward a live birth was a synergistic combination of two modifiable factors: a decrease in body mass index and an increase in the number of embryos available for transfer. The average treatment effect for increased embryo number was estimated at 0.068, meaning that, on average across the cohort, having more embryos raised the predicted probability of cumulative live birth by about seven percentage points. The average treatment effect for decreased BMI was -0.010, a smaller average effect but one with striking heterogeneity. When the researchers examined subgroups, they found that BMI intervention showed its most robust causal efficacy among young high-responder patients with obesity, where the conditional average treatment effect reached -0.105, roughly a ten-and-a-half percentage point change in predicted probability. In other words, the benefit of weight reduction is not uniform across the population; it is concentrated in a specific, identifiable subgroup, which is precisely the kind of insight that individualized medicine requires.

The third innovation concerns the decision threshold itself. Most prediction studies report a single cutoff, often 0.5, above which patients are classified as positive. But the clinically optimal cutoff depends on the relative costs of false positives and false negatives, which vary with the decision at hand. The researchers used interactive decision curve analysis, or iDCA, to explore how the net benefit of acting on the model’s predictions changes across different thresholds. Net benefit is a metric that quantifies the clinical value of a prediction model by weighing the true positives it identifies against the harm of unnecessary interventions triggered by false positives. For this cohort, the optimal threshold was 0.429, yielding a net benefit of 0.331. Crucially, the model maintained robust net benefit, ranging from 0.312 to 0.379, across a broad threshold band from 0.3 to 0.5. This band structure is arguably more useful to clinicians than any single number, because it defines a zone within which the model remains clinically valuable, giving practitioners flexibility to adjust the cutoff according to individual patient preferences and risk tolerance, the very element the authors identified as missing from prior models.

The translational gap the study targets is a familiar one in medical artificial intelligence. Many published prediction models achieve impressive statistical performance in a journal but never influence a clinical conversation. Part of the problem is that a raw probability, however accurate, does not tell a patient or a physician what to do. By pairing the prediction with counterfactual explanations, the model can tell a specific couple what would need to change for their predicted probability to cross the decision threshold, and by validating the threshold band with decision curve analysis, the study anchors those explanations in a framework of clinical utility. This combination of prediction, explanation, and threshold optimization represents a template that other areas of reproductive medicine, and predictive medicine more broadly, could follow.

Several caveats deserve emphasis. The study is retrospective and non-interventional, which means the causal estimates, however carefully derived, describe effects inferred from observational data rather than from randomized interventions. The cohort comes from a single region of China, and although temporal validation within that setting was robust, transportability to populations with different demographics, treatment protocols, and laboratory standards remains to be demonstrated. The BMI finding, in particular, should be interpreted as evidence that weight is a promising interventional target in a specific subgroup, not as a prescription for all patients. The authors themselves frame the work as identifying causally augmented, temporally validated decision thresholds with balanced discrimination and robust transportability for cumulative live birth strategies, a measured claim consistent with the evidence presented.

Nevertheless, the practical output is immediately accessible. The team deployed the model as a publicly available web platform, hosted at fertility-yts.shinyapps.io/CLBR_GBM, where both patients and clinicians can enter individualized inputs and receive a predicted cumulative live birth probability. For a couple weighing whether to proceed with another transfer, take a pause, or consider weight reduction before a new cycle, a tool that combines a validated probability estimate with an honest account of which changes are likely to matter, and by how much, fills a genuine gap. The study was approved by the Clinical Trial Ethics Committee of Yantaishan Hospital and conducted in accordance with the Declaration of Helsinki, using anonymized data collected after routine informed consent. As machine learning continues to move into fertility clinics, this work suggests that the models most likely to earn clinical trust will be those that can answer not only what will happen, but what could be done about it.

Subject of Research: Causality-enhanced machine learning prediction of cumulative live birth rate in in vitro fertilization

Article Title: Causality enhanced machine learning for cumulative live birth rate prediction with threshold band optimization in in vitro fertilization

Article References: Zhang, A., Huang, X., Han, Z., Yang, Q., Sun, X., & Wang, D. (2026). Causality enhanced machine learning for cumulative live birth rate prediction with threshold band optimization in in vitro fertilization. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02251-2

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02251-2

Keywords: in vitro fertilization, cumulative live birth rate, machine learning, gradient boosting, causal inference, counterfactual explanation, double machine learning, decision curve analysis, body mass index, personalized prediction, reproductive medicine, temporal validation

The retrospective cohort study, led by Reweiguli Aihaiti and colleagues at Ruijin Hospital, affiliated with the Shanghai Jiao Tong University School of Medicine, drew on 3,285 patients who underwent frozen embryo transfer at the hospital’s Reproductive Medical Center between January 2015 and December 2022. After applying strict exclusion criteria, the team analyzed 2,543 women who delivered singleton live births and had complete pre-pregnancy menstrual cycle data. Participants were divided into four groups according to cycle length: 27 days or fewer, 28 to 31 days, 32 to 35 days, and 36 days or more. The reference category, encompassing roughly 71 percent of the cohort, was the conventional 28-to-31-day cycle, long considered the physiological gold standard.

The statistical architecture of the study was deliberately conservative. The investigators used multivariable logistic regression to estimate adjusted odds ratios for gestational diabetes and gestational hypertension, controlling for an unusually broad set of potential confounders: maternal age, body mass index, parity, causes and duration of infertility, fertilization method, ovarian stimulation protocol, number of transferable embryos, endometrial preparation method, embryo stage, and the number of embryos transferred. Patients with comorbidities known to disrupt both menstruation and pregnancy outcomes were excluded outright, and none of the participants had used oral contraceptives in the three months preceding their transfer, removing another potential source of distortion.

The results were striking in their consistency. Women with prolonged cycles of 36 days or longer had a 54 percent higher adjusted odds of developing gestational diabetes compared with women in the reference group, with an adjusted odds ratio of 1.54 and a 95 percent confidence interval of 1.14 to 2.09. Their adjusted odds of gestational hypertension were 60 percent higher, at 1.60. Perhaps more unexpectedly, cycles of 32 to 35 days, only modestly longer than normal, were also associated with a 59 percent increase in the odds of gestational hypertension. The raw incidence rates told the same story: gestational diabetes affected 25.6 percent of women with prolonged cycles, and gestational hypertension reached 12.2 percent in that group, both the highest figures across the four cycle-length categories.

Shorter cycles told the opposite story. Women whose cycles ran 27 days or fewer had roughly half the adjusted odds of developing gestational diabetes, with an adjusted odds ratio of 0.49, compared with the reference group. This protective association, the authors note, had been hinted at in earlier population-based research but had never been demonstrated in an IVF population free of polycystic ovary syndrome. The dose-response-like gradient, in which risk rises as cycle length lengthens and falls as it shortens, strengthens the biological plausibility of the association and argues against a statistical fluke.

What could a longer menstrual cycle possibly have to do with the way a placenta handles glucose or a maternal vasculature tolerates the hemodynamic load of pregnancy? The authors point to a chain of endocrine mechanisms documented in prior literature. Prolonged cycles are associated with hyperinsulinemia, and chronically elevated insulin suppresses hepatic production of sex hormone-binding globulin, which in turn raises levels of free circulating testosterone. Both insulin resistance and androgen excess are established risk factors for gestational diabetes. Longer cycles have also been linked to abnormalities in lipid metabolism and broader metabolic disturbance, conditions that independently predispose women to impaired glucose tolerance during pregnancy.

The connection to gestational hypertension may run through related but distinct physiology. Gestational glucose intolerance has previously been tied to hypertensive disorders of pregnancy, independent of obesity and blood glucose levels, in part because insulin resistance drives both inflammatory dysregulation and vascular dysfunction. The new study adds a novel piece of evidence by linking prolonged menstrual cycles, a marker of long-term endocrine milieu, to hypertension risk specifically in the absence of polycystic ovary syndrome. The finding dovetails with large epidemiological studies showing that women with long or irregular cycles face elevated lifetime risks of cardiovascular disease, ischemic heart disease, heart failure, hypertension, and type 2 diabetes. In a nationwide UK cohort of more than 700,000 women, cycle irregularity predicted a cluster of cardiometabolic outcomes years later.

The clinical implications are immediate for the fertility field. Frozen embryo transfer is performed under tightly controlled hormonal conditions, with endometrial preparation through natural cycles or hormone replacement protocols and progesterone support timed to precise endometrial thresholds. Yet even within this engineered environment, the underlying metabolic predisposition of the patient appears to assert itself. The authors argue that menstrual cycle length should be treated as a risk factor warranting screening before IVF treatment begins, and that combining cycle characteristics with body mass index in routine pre-treatment evaluations could identify women who would benefit from early glucose monitoring, blood pressure surveillance, and preventive intervention during pregnancy.

The study is not without limitations, and the authors are candid about them. The retrospective design precluded measurement of baseline insulin and lipid profiles, so the proposed mechanisms remain inferential rather than directly demonstrated. The cohort was restricted to frozen embryo transfer cycles, leaving open the question of whether the same associations hold for fresh transfers, where supraphysiological estradiol levels add their own metabolic noise. Supplementary analyses stratifying the population more finely showed that women with extraordinarily long cycles of 60 days or more had numerically elevated risks of both complications, with adjusted odds ratios of 2.06 for gestational diabetes and 1.88 for gestational hypertension, but the sample in that subgroup was too small for the results to reach statistical significance.

Even so, the study represents a first. No previous investigation had examined the relationship between menstrual cycle length and pregnancy complications in women without polycystic ovary syndrome undergoing IVF with frozen embryo transfer, a population that continues to grow as freeze-all strategies become standard practice in clinics worldwide. The message for patients is not alarm but attention: a menstrual cycle that reliably stretches beyond five weeks is not merely a fertility inconvenience or an aesthetic quirk of biology. It may be a visible readout of an invisible metabolic state, one that shapes pregnancy outcomes and, according to a growing body of evidence, long-term cardiovascular health. Larger prospective studies will be needed to confirm the findings and to test whether early intervention, from lifestyle modification to pharmacologic glucose management, can convert this new risk marker into a preventable outcome.

Subject of Research: The association between pre-pregnancy menstrual cycle length and the risk of gestational diabetes mellitus and gestational hypertension in women without PCOS undergoing frozen embryo transfer.

Article Title: Associations of menstrual cycle length with GDM and gestational hypertension in frozen embryo transfer

Article References: Aihaiti, R., Zhu, Z., Wu, X., Shen, Z., & Niu, Z. (2026). Associations of menstrual cycle length with GDM and gestational hypertension in frozen embryo transfer. Journal of Ovarian Research, 19(1), Article 277. https://doi.org/10.1186/s13048-026-02168-w

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02168-w

Keywords: menstrual cycle length, gestational diabetes mellitus, gestational hypertension, frozen embryo transfer, in vitro fertilization, polycystic ovary syndrome, insulin resistance, pregnancy complications, reproductive medicine, cardiometabolic risk, IVF outcomes, retrospective cohort study

The findings, drawn from nine randomized controlled trials encompassing 2,481 women with recurrent implantation failure, are cautiously encouraging. The researchers, led by Mohammadamin Parsaei of Tehran University of Medical Sciences, found that women whose embryos underwent laser-assisted hatching had significantly higher rates of clinical pregnancy, ongoing pregnancy, and live birth compared with women who received no such intervention. Perhaps most strikingly, the technique was associated with a significantly lower rate of miscarriage, and the live birth and miscarriage results carried moderate certainty in the researchers’ formal quality assessment, a level of confidence that is rare in this literature.

To understand why the technique exists at all, one has to look at the biology of the earliest days of embryonic development. Every embryo begins life encased in the zona pellucida, a glycoprotein shell that protects the oocyte and early embryo, mediates sperm recognition, and prevents premature implantation. As the embryo reaches the blastocyst stage, it must hatch from this shell, expanding, contracting, and finally rupturing it before it can make contact with the uterine lining. Scientists have long hypothesized that some embryos, particularly those cultured in the laboratory or derived from older oocytes with hardened or thickened zonae, may struggle to complete this escape, and that a laboratory-assisted exit could tip the balance toward successful implantation.

Assisted hatching began as a micromanipulation procedure in the late 1980s, when researchers first partially opened the zona pellucida to facilitate fertilization and later to aid hatching. Early methods relied on mechanical piercing or acidic chemical drilling, both of which carried risks of embryo damage and required considerable manual skill. The introduction of non-contact diode and ultraviolet lasers in the 1990s transformed the procedure: a focused beam could now thin a precise section of the shell, or drill a controlled opening, in seconds, with minimal handling and reproducible results. Today, laser-assisted hatching is performed in two main variants, zona thinning and zona drilling, and the new analysis examined both approaches in its subgroup analyses.

For the new study, the team searched PubMed, Web of Science, Scopus, and Embase on January 22, 2025, for randomized controlled trials comparing embryo transfer outcomes after laser-assisted hatching against controls specifically in women with recurrent implantation failure. They followed the PRISMA 2020 reporting guidelines, assessed risk of bias with the Cochrane RoB 2 tool, pooled outcomes using random-effects meta-analyses expressed as log odds ratios, and graded the certainty of the evidence with the GRADE framework. Publication bias was probed with funnel plots, Egger’s regression test, and the trim-and-fill method, while subgroup analyses stratified results by mean patient age, overall risk of bias, and the specific hatching technique used.

The headline numbers tell a consistent story. Clinical pregnancy was significantly more likely in the hatched group, with a log odds ratio of 0.643 and a 95 percent confidence interval of 0.267 to 1.019, though the underlying trials showed substantial heterogeneity and the certainty of this evidence was rated very low. Ongoing pregnancy showed a similar pattern, with a log odds ratio of 0.811 and very low certainty. Live birth, the outcome that matters most to patients, was significantly improved with a log odds ratio of 0.519 and remarkably low heterogeneity between studies, earning a moderate certainty rating. Miscarriage was significantly reduced, with a log odds ratio of minus 0.632, zero heterogeneity, and moderate certainty.

Not every result favored the intervention. Implantation rates per transferred embryo did not differ significantly between groups, with a log odds ratio of 0.691 whose confidence interval crossed zero and very high heterogeneity of 87.14 percent, suggesting the trials measured this outcome in markedly different ways. Multiple pregnancy rates per clinical pregnancy were also statistically indistinguishable between groups, with zero heterogeneity and moderate certainty, a finding that will reassure clinicians who have worried that weakening the zona pellucida might encourage the embryo to split into identical twins.

The divergence between the live birth and miscarriage results on one hand and the implantation result on the other is scientifically intriguing. If laser-assisted hatching does not measurably increase the proportion of embryos that implant, yet more pregnancies ultimately end in a take-home baby and fewer end in miscarriage, one possible interpretation is that the technique benefits embryos that would otherwise implant abnormally or fail shortly after attachment. The authors themselves, however, urge restraint, noting that the heterogeneity observed across trials and the generally low quality of the available studies mean these conclusions remain provisional, and that high-quality, large-scale randomized controlled trials are needed to confirm them.

The new analysis arrives amid a shifting regulatory and clinical landscape. The American Society for Reproductive Medicine’s 2022 guideline on assisted hatching concluded that the procedure should not be offered routinely or even as a treatment for patients with an anticipated poor prognosis, citing insufficient evidence of benefit. A 2021 Cochrane review of assisted hatching across all IVF and ICSI patients similarly found no clear benefit and raised concerns about possible harms. Yet those syntheses pooled broad populations, including many patients with no implantation problems at all, which may have diluted any genuine effect in the subgroup that matters. By restricting the analysis to women with documented recurrent implantation failure, the new study tests a more focused hypothesis, and its positive live birth finding stands in meaningful tension with the earlier, broader reviews.

For the roughly ten percent of IVF patients who experience repeated implantation failure, the practical takeaway is one of measured hope rather than a change in standard care. The evidence now suggests that laser-assisted hatching, a quick and technically straightforward laboratory procedure, may improve the odds of a live birth in this difficult population without increasing multiple pregnancies, and that it may reduce the heartbreak of miscarriage. But with several of the key outcomes graded at very low certainty, and with the field still lacking a universally agreed definition of recurrent implantation failure itself, patients and clinicians alike will be watching for the large, well-designed trials that the authors say are now essential. Until then, the laser remains a promising but unproven ally in one of fertility medicine’s most stubborn challenges.

Subject of Research: Laser-assisted hatching and embryo transfer outcomes in patients with recurrent implantation failure

Article Title: Outcomes of Embryo Transfer Following Laser-assisted Hatching in Patients with Recurrent Implantation Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Article References: Parsaei, M., Karimi, E., Seifi, P., Dehghan Tarzjani, M., & Tarafdari, A. (2026). Outcomes of Embryo Transfer Following Laser-assisted Hatching in Patients with Recurrent Implantation Failure: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02219-z

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02219-z

Keywords: laser-assisted hatching, recurrent implantation failure, embryo transfer, in vitro fertilization, meta-analysis, live birth rate, miscarriage, zona pellucida, clinical pregnancy, assisted reproductive technology, randomized controlled trials, reproductive medicine

The drug at the center of the question is propofol, a short-acting agent that has become the workhorse of general anesthesia for oocyte retrieval worldwide. Propofol acts rapidly on the central nervous system by modulating GABA receptors, producing sedation within seconds and clearing quickly once the infusion stops, which makes it ideal for procedures lasting under an hour. But propofol is also lipophilic and biologically active, and laboratory studies have suggested it can cross the follicular barrier and appear in follicular fluid. Animal and in vitro experiments have raised the theoretical possibility that anesthetic exposure around the time of fertilization could perturb calcium signaling, spindle dynamics, or mitochondrial activity in the oocyte, processes that are critical in the hours and days that follow. Whether these laboratory signals translate into any meaningful effect on real human embryos has remained stubbornly unclear.

The research team, led by Xingwu Wu and colleagues, tackled the problem with a tool that only recently became standard in advanced embryology laboratories: time-lapse imaging, or TLI. Conventional embryo assessment relies on brief, discrete snapshots, with embryologists lifting embryos from their incubators once a day to grade them under a microscope. That approach misses nearly everything that matters, because the most informative events of early development, including pronuclear appearance, syngamy, and each successive cell division, unfold in the dark between observations. Time-lapse incubators solve this by photographing each embryo every few minutes without disturbing it, generating a continuous film of development. The resulting timeline of events, known as morphokinetics, gives researchers an exquisitely sensitive readout of embryonic health, and it is precisely the kind of instrument needed to detect subtle delays or disruptions that an anesthetic agent might cause.

Between April and July 2023, the team enrolled 210 infertile women undergoing IVF or intracytoplasmic sperm injection at their center. Of these, 101 received propofol-based general anesthesia during oocyte retrieval, while 109 underwent the procedure without general anesthesia and served as the control group. Because the study was retrospective, the investigators took care to verify that the two groups were comparable before drawing any conclusions, and indeed baseline characteristics and ovarian stimulation outcomes were similar across the board. The number of oocytes retrieved did not differ significantly, nor did the hormonal profiles, laboratory metrics, or stimulation parameters that might otherwise confound a comparison of embryo quality. This methodological grounding matters enormously in anesthesia research, where differences in patient populations can easily masquerade as drug effects.

The primary outcomes were the morphokinetic parameters captured by the time-lapse system, and here the study delivered its most important findings. The researchers tracked the timing of pronuclear appearance, the moment when the two parental genetic packages first become visible as distinct structures within the fertilized egg, as well as the timings of cleavage to the two-, three-, four-, five-, and eight-cell stages, denoted t2 through t8. They also measured the onset of compaction, the start of blastulation, the time to full blastocyst formation, and the timing of blastocyst expansion. Across every one of these landmarks, the embryos of women who had received propofol were statistically indistinguishable from those of women who had not. The developmental clocks of the two groups ticked in unison, hour by hour, from fertilization through the blastocyst stage.

Secondary outcomes told the same story at the level of the laboratory and the clinic. The rate of normal fertilization, defined by the appearance of two pronuclei, was comparable between groups, as was the cleavage rate, the proportion of day-three embryos judged to be of good quality, and the rate at which embryos progressed to blastocysts. When fresh embryos were transferred, clinical pregnancy rates, miscarriage rates, and live birth rates were all similar between the anesthesia and control groups. In other words, the chain of events that begins with an anesthetized egg retrieval and ends with a take-home baby showed no detectable weak links attributable to propofol. For a field in which patients scrutinize every decision for possible harm to their chances, this consistency across endpoints carries real weight.

The technical strength of the study lies in its use of continuous morphokinetic monitoring rather than static morphology grading alone. Static grading can only describe what an embryo looks like at a given moment, whereas morphokinetics reveals how it got there, including subtle timing anomalies such as direct cleavage from one cell to three, prolonged pronuclear fading, or abnormal synchrony between cell divisions, all of which have been associated with poorer implantation potential in prior literature. Had propofol exposure imposed even a modest developmental delay or increased the frequency of atypical cleavage patterns, a time-lapse platform of this kind would be well positioned to detect it. The absence of any such signal, across a battery of timed landmarks, therefore represents a genuinely rigorous form of negative evidence rather than a simple failure to observe gross abnormalities.

As with any retrospective cohort study, the findings come with caveats that the authors and independent readers alike should keep in view. Allocation to anesthesia was not randomized, so residual confounding by indication, meaning systematic differences between patients who chose or were assigned general anesthesia and those who did not, cannot be entirely excluded, even with comparable baseline characteristics. The single-center design, while ensuring uniform laboratory protocols and embryology practices, means the results reflect one institution’s patient population and clinical routines. The sample size of 210 participants, though adequate for detecting moderate differences in morphokinetic timing, may not have been powered to exclude very small effects on rare outcomes such as miscarriage. The authors also note that the study was approved by their institutional ethics committee with written informed consent from all participants, and it was funded by the Natural Science Foundation of Jiangxi Province.

Even with those limitations, the study lands at a consequential moment. Propofol remains the default anesthetic for oocyte retrieval in most fertility centers because it offers rapid onset, swift recovery, and reliable patient comfort during an uncomfortable transvaginal needle procedure, and alternatives such as conscious sedation or paracervical blocks each carry their own trade-offs in efficacy and tolerability. Persistent uncertainty about embryonic effects has left some patients and clinicians to weigh comfort against a feared, but unquantified, reproductive risk. By combining a clinically relevant exposure, a sensitive continuous imaging platform, and a full chain of outcomes from fertilization through live birth, the Nanchang team has provided the kind of reassuring, mechanistically informed data that the field has needed. The message for patients heading into an egg retrieval is straightforward: choosing general anesthesia with propofol to stay comfortable during the procedure does not appear to cost their embryos anything measurable, either in the incubator or in the clinic.

Subject of Research: Effects of propofol general anesthesia during oocyte retrieval on embryo morphokinetics and IVF clinical outcomes

Article Title: Effects of general anesthesia with propofol during oocyte retrieval on embryo morphokinetics and clinical outcomes: a retrospective cohort study

Article References: Wu, X., Zhong, Y., Xia, L., Huang, J., Chen, J., Zhang, Z., Liu, P., Tian, L., Tan, J., Chen, H., Xin, C., Huang, Z., & Zhao, Y. (2026). Effects of general anesthesia with propofol during oocyte retrieval on embryo morphokinetics and clinical outcomes: a retrospective cohort study. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02289-2

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02289-2

Keywords: propofol, general anesthesia, oocyte retrieval, IVF, ICSI, embryo morphokinetics, time-lapse imaging, blastocyst, clinical pregnancy, live birth, fertility treatment, retrospective cohort study

The research, led by Hui Jeong An, Sung Hwan Cho, and colleagues at CHA University and CHA Bundang Medical Center, with corresponding authors Jin-Bae Kim of Kyung Hee University Hospital and Nam Keong Kim of CHA University, focused on four specific microRNAs: miR-10a, miR-30c, miR-181a, and miR-499b. MicroRNAs are short, non-coding RNA molecules, roughly eighteen to twenty-five nucleotides in length, that do not encode proteins themselves. Instead, they act as fine-tuners of gene expression. After being transcribed from the genome and processed through a well-characterized cellular machinery involving enzymes such as Drosha and Dicer, mature microRNAs are loaded into the RNA-induced silencing complex, where they bind to target sequences, typically within the three-prime untranslated region of messenger RNAs. This binding either promotes degradation of the target transcript or blocks its translation into protein. Because a single microRNA can regulate dozens or even hundreds of target genes, changes in microRNA sequence or abundance can ripple outward across entire biological pathways.

What makes microRNAs especially interesting from a genetic standpoint is that their genes themselves can harbor single nucleotide polymorphisms, or SNPs, which are positions in the DNA sequence where a single letter of the genetic code varies between individuals. When such a variant sits within the mature microRNA sequence or its precursor, it can alter how the microRNA folds, how it is processed, or which messenger RNAs it binds. In effect, these polymorphisms function as heritable knobs that dial the activity of gene regulatory networks up or down. Previous studies, including earlier work by some of the same Korean investigators on miR-146a, miR-149, miR-196a2, and miR-499 in the context of recurrent pregnancy loss, have suggested that such variants could plausibly influence reproductive outcomes, although findings across populations have often been inconsistent.

To interrogate this question systematically, the team enrolled 169 Korean women diagnosed with recurrent implantation failure and compared them against 281 fertile controls. Genomic DNA was extracted from peripheral blood samples, and the researchers genotyped four variants, denoted miR-10a A>T, miR-30c A>G, miR-181a T>C, and miR-499b A>G, using two complementary laboratory techniques: polymerase chain reaction with restriction fragment length polymorphism analysis, a classic method in which a variant either preserves or abolishes a restriction enzyme’s cutting site so that genotypes can be read from fragment sizes on a gel, and real-time polymerase chain reaction, which offers a faster, fluorescence-based genotyping readout. The study protocol received ethical approval from the Institutional Review Board of CHA Bundang Medical Center, and all participants provided written informed consent.

The first and perhaps most important analytical result was a negative one: when the researchers compared the overall RIF group with fertile controls, none of the four microRNA polymorphisms showed a statistically significant independent association with implantation failure risk. This kind of null result is common in complex-disease genetics and underscores why single-variant analyses frequently fail to capture the biology of multifactorial conditions. However, the picture changed when the investigators stratified the RIF group by clinical and laboratory characteristics. Among women who had experienced four or more failed implantation attempts, carriers of the miR-499b AG genotype showed a significantly elevated risk, with an adjusted odds ratio of 1.908 and a p-value of 0.021. Similarly, the miR-181a TC plus CC genotypes appeared to raise risk specifically among women with lower platelet counts, while the miR-30c AG plus GG genotypes consistently behaved in a protective manner, an effect that was particularly striking in subgroups of women with a body mass index of 25 kilograms per square meter or higher, where the adjusted odds ratio fell to 0.104, and in women with shorter activated partial thromboplastin times, where the adjusted odds ratio was 0.216.

These subgroup signals gain biological plausibility from what is already known about the targets of these microRNAs. PAI-1, the plasminogen activator inhibitor-1, is the principal inhibitor of tissue-type and urokinase-type plasminogen activators in the fibrinolytic system, and it is a confirmed target of miR-10a, miR-30c, and miR-181a, and a predicted target of miR-499b. PAI-1 is far from an arbitrary choice in a reproduction study. Successful implantation requires that trophoblast cells invade the endometrium in a tightly regulated fashion, a process that depends on a carefully choreographed balance between extracellular matrix degradation and coagulation control. Prior literature has linked PAI-1 expression to endometrial receptivity, to the invasive capacity of endometrial cells, and to disorders of female reproduction ranging from endometriosis to recurrent pregnancy loss. The PAI-1 4G/5G polymorphism has itself been studied in relation to implantation outcomes, and experimental work in endothelial and endometrial cancer cell models has shown that microRNAs of the 181 family and miR-10a can modulate PAI-1 levels and thereby influence fibrinolysis and cellular invasion.

Because of this mechanistic connection, the Korean team went beyond the conventional single-variant association analysis and tested whether combinations of microRNA polymorphisms and PAI-1 genotypes interacted synergistically to shape RIF risk. This type of multilocus analysis is statistically delicate, since the number of possible genotype combinations grows exponentially with each additional locus, but it can reveal gene-gene interactions that no individual variant analysis would detect. The results were striking. A three-locus combination involving PAI-1 and miR-181a, denoted the A-T-C combination, was strongly associated with susceptibility to RIF, with an odds ratio of 2.644, a p-value of 0.002, and a false discovery rate corrected p-value of 0.014, indicating that the signal survived correction for multiple testing. Conversely, a different combination, the G-T-G pairing of PAI-1 with miR-30c, was found exclusively among the fertile controls and was associated with a strong protective effect, with an odds ratio of just 0.055, a p-value of 0.002, and a false discovery rate corrected p-value of 0.014. In other words, women carrying that particular genetic configuration were dramatically underrepresented among those who experienced repeated implantation failure.

The authors are appropriately measured about the interpretive limits of their work. Certain multilocus allele combinations involving PAI-1 did show suggestive associations with RIF risk, but the estimates for rare combinations came with wide confidence intervals and, as the researchers themselves emphasize, should be treated as exploratory hypotheses rather than established findings. Genetic association studies in reproductive medicine have a checkered history of promising signals that fail to replicate, particularly when sample sizes are modest, as is nearly inevitable in a condition defined by a specific and relatively uncommon clinical presentation. The RIF group in this study comprised 169 women, a substantial number for this field but still small by the standards of genome-wide association research, and the cohort was restricted to Korean women, which raises questions about generalizability across ethnic groups where allele frequencies and linkage patterns may differ.

Nevertheless, the conceptual contribution of the study is significant. By anchoring the analysis in a defined biological axis, microRNAs that regulate PAI-1, the investigators moved beyond blind variant scanning and toward a pathway-informed framework for understanding implantation genetics. The protective effect of miR-30c AG plus GG genotypes in women with higher BMI and shorter aPTT, the risk effect of miR-499b AG among women with the most failed cycles, and the strongly interacting PAI-1 and miR-181a haplotypes all point toward the same underlying biology: the coagulation and invasion machinery of the endometrium, fine-tuned by post-transcriptional regulation, appears to be one of the determinants of whether an embryo can successfully establish a pregnancy. This is consistent with endometrial transcriptomic studies showing that microRNA expression profiles within the window of implantation differ between women with repeated failure and fertile individuals.

What might this mean clinically, and what should happen next? In the near term, nothing in this study supports routine genetic screening of IVF patients for these microRNA variants, since none of the individual polymorphisms predicted risk in the overall population and the stratified findings require independent validation. But the longer-term implications are tantalizing. If future studies in larger, multiethnic cohorts confirm that PAI-1 and microRNA genotype combinations stratify implantation failure risk, such information could eventually inform personalized protocols, guiding decisions about anticoagulation, endometrial preparation, or the intensity of preimplantation evaluation for women at high genetic risk. The study also reinforces a broader lesson that is reshaping human genetics: regulatory variation, including variation within microRNA genes, matters as much as variation within protein-coding sequences, and it is the architecture of interactions, not the influence of any single variant, that most often distinguishes patients from controls. Funded in part by Korea’s National Research Foundation, the Korea Health Industry Development Institute, and related agencies, and conducted under rigorous ethical oversight, this work offers the fertility research community a carefully documented set of hypotheses and a demonstration that the genetics of implantation, like implantation itself, is fundamentally a story of cooperation among molecular players rather than the performance of any one actor.

Subject of Research: Association of microRNA polymorphisms and PAI-1 gene-gene interactions with recurrent implantation failure in Korean women

Article Title: Association of miRNA (miR-10a, miR-30c, miR-181a, and miR-499b) Polymorphisms and Their Interactions with PAI-1 in Recurrent Implantation Failure in Korean Women

Article References: An, H. J., Cho, S. H., Ko, J. E., Kim, J. H., Park, H. W., Kim, Y. R., Ahn, E. H., Kim, J.-B., & Kim, N. K. (2026). Association of miRNA (miR-10a, miR-30c, miR-181a, and miR-499b) Polymorphisms and Their Interactions with PAI-1 in Recurrent Implantation Failure in Korean Women. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02188-3

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02188-3

Keywords: recurrent implantation failure, microRNA, PAI-1, single nucleotide polymorphism, in vitro fertilization, fertility genetics, gene-gene interaction, miR-181a, miR-30c, fibrinolysis, endometrial receptivity, Korean women

The study, led by Emily A. Clarke of the Icahn School of Medicine at Mount Sinai and Reproductive Medicine Associates of New York, together with colleagues including Alan B. Copperman, examined 203 patients who experienced early pregnancy loss and subsequently underwent a single euploid embryo transfer, a procedure in which a genetically screened embryo with the correct number of chromosomes is transferred one at a time. Of these patients, 88 were managed medically, typically with misoprostol, while 115 underwent surgical management, usually dilation and curettage. Because all participants received embryos confirmed to be chromosomally normal through preimplantation genetic testing, the researchers were able to isolate the contribution of the uterine environment itself, removing the confounding noise of embryo aneuploidy, which is the leading cause of early miscarriage and failed implantation.

The primary outcome was the change in endometrial thickness between the cycle in which the pregnancy was lost and the subsequent frozen embryo transfer cycle. Endometrial thickness, measured by transvaginal ultrasound, is one of the most closely watched parameters in reproductive medicine because a lining thinner than seven millimeters is associated with markedly reduced implantation and live birth rates. Large analyses of tens of thousands of embryo transfers, including a 2022 study of more than 96,000 autologous transfers published in Fertility and Sterility, have demonstrated a graded relationship between lining thickness and success, making any iatrogenic thinning of the endometrium a legitimate clinical concern.

What the researchers found was striking in its neutrality. Between the initial and subsequent transfer cycles, endometrial thickness changed by an average of plus 0.3 millimeters in the medically managed group and plus 0.1 millimeters in the surgically managed group, a difference that was statistically indistinguishable with a P value of 0.65. In the subsequent transfer cycle itself, the average lining measured 9.4 millimeters in the medical group and 9.1 millimeters in the surgical group, again with no significant difference. Cycle cancellation because of a persistently thin lining, defined as less than seven millimeters, was rare in both arms, occurring in 3.4 percent of medically managed patients and 2.6 percent of surgically managed patients. In practical terms, the surgical instrumentation that many feared might scar the uterine cavity did not measurably impair the endometrium’s ability to proliferate under hormonal preparation.

This finding carries particular weight because prior literature had raised genuine alarms. Earlier studies, including work by Shufaro and colleagues in 2008 and investigations by Davar and Azumaguchi, described a thin, unresponsive endometrium as a possible complication of surgical curettage, with some patients developing linings that failed to thicken even with high doses of estrogen. Asherman’s syndrome, the formation of intrauterine adhesions after aggressive curettage, remains a recognized and sometimes devastating consequence of uterine instrumentation. The new data do not erase those risks, which are uncommon but real, yet they suggest that in the specific population of IVF patients destined for euploid embryo transfer, routine dilation and curettage for early pregnancy loss does not produce a detectable average penalty on endometrial development.

The secondary outcomes told a more nuanced story. While live birth rates in the subsequent transfer cycle were statistically similar between the two groups, 48.8 percent among medically managed patients versus 40.7 percent among surgically managed patients, the rate of clinical pregnancy loss after a positive pregnancy test was significantly higher in the surgical cohort, at 15.7 percent compared with 4.9 percent. After adjusting for potential confounders, surgical management carried an adjusted odds ratio of 3.72 for subsequent pregnancy loss, with a 95 percent confidence interval of 1.11 to 12.47. The authors stopped short of claiming causation, and the absolute difference, roughly eleven percentage points, is modest, but the signal is biologically plausible. Instrumentation of the uterine cavity could theoretically alter the endometrium’s receptivity at a level finer than thickness alone can capture, affecting the molecular dialogue between embryo and lining that governs implantation and placentation.

Endometrial receptivity is a complex process involving the synchronized expression of hundreds of genes, the maturation of the epithelial pinopodes, the recruitment of immune cells, and the development of an adequate blood supply. Research into implantation failure has implicated inflammatory markers and disruptions of this delicate immunological environment. A curettage procedure induces a controlled injury and an inflammatory repair response, and while the lining may regenerate to a normal thickness, subtle alterations in its functional quality could persist. The elevated miscarriage rate observed in the surgical group, despite equivalent lining measurements and equivalent live birth rates among those pregnancies that did progress, hints at exactly this kind of subclinical functional difference, one that ultrasound cannot see but that may manifest as an early pregnancy that implants and then fails.

The study’s design deserves scrutiny. As a single-center retrospective cohort, it cannot randomize patients to treatment arms, and the choice between medical and surgical management was made by patients and physicians based on clinical circumstances, introducing the possibility of selection bias. Patients with heavier bleeding, retained tissue, or hemodynamic instability are more likely to undergo surgery, and these same factors might independently affect subsequent reproductive outcomes. The sample size of 203, while respectable for a single-center study, limits statistical power for rare outcomes, and the wide confidence interval around the miscarriage odds ratio reflects that uncertainty. Nevertheless, the use of euploid single embryo transfers represents a methodological strength that few prior studies on this question have enjoyed, because it controls for the single largest determinant of IVF success, namely embryo chromosomal competence.

For clinicians, the findings translate into a more evidence-based framework for counseling. Patients with early pregnancy loss who have frozen euploid embryos waiting can be told that neither medical nor surgical management appears to compromise their endometrial thickness or their overall chances of a live birth in the next transfer cycle. Those who prefer the certainty and speed of a surgical procedure, or who require it for clinical reasons, can be reassured that the lining typically recovers fully. At the same time, the elevated loss rate in the surgical group gives clinicians a legitimate data point to discuss, particularly for patients with a history of recurrent pregnancy loss who may be especially sensitive to any factor that raises miscarriage risk. The decision should remain individualized, weighing the efficacy, side effects, and completion rates of misoprostol against the operating room requirements of curettage.

The research, presented orally at the American Society for Reproductive Medicine’s scientific congress in Denver in October 2024 before its peer-reviewed publication, adds to a growing body of work aimed at demystifying what happens to the uterus after miscarriage and how best to prepare it for the next attempt. Early pregnancy loss affects roughly one in ten recognized pregnancies, and among IVF patients the emotional and financial stakes of each subsequent cycle are exceptionally high. By demonstrating that endometrial recovery is robust across both management pathways, and by flagging a modest but significant difference in subsequent pregnancy loss, the study gives patients and physicians something they have long lacked: quantitative, embryo-quality-controlled evidence on which to base one of the most common and consequential decisions in reproductive medicine. The authors note that de-identified data are available upon reasonable request, and they emphasize that these findings may help guide counseling for patients navigating the difficult intersection of miscarriage management and fertility treatment.

Subject of Research: How medical versus surgical management of early pregnancy loss affects endometrial thickness and outcomes of subsequent euploid embryo transfers in IVF patients

Article Title: Management of Early Pregnancy Loss: Reproductive Outcome in Subsequent Euploid Embryo Transfers

Article References: Management of Early Pregnancy Loss: Reproductive Outcome in Subsequent Euploid Embryo Transfers. (n.d.). https://doi.org/10.1007/s43032-026-02200-w

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02200-w

Keywords: early pregnancy loss, dilation and curettage, misoprostol, endometrial thickness, euploid embryo transfer, in vitro fertilization, live birth rate, clinical pregnancy loss, reproductive medicine, miscarriage management, Management, Early

Embryo transfer is the final procedural stage of IVF, in which an embryo is placed inside the uterus through a thin catheter passed through the cervix. Although the technique is usually brief, it is considered a particularly sensitive part of treatment because the embryo must be delivered without causing unnecessary trauma, bleeding, uterine contractions, or difficulty navigating the reproductive tract. Only about one in three embryo transfers results in pregnancy, although outcomes vary substantially according to age, embryo quality, uterine conditions, fertility diagnosis, and laboratory procedures.

The review focused on techniques designed to alter the physical conditions encountered by the catheter before the embryo is released. One widely used method involves asking the patient to fill her bladder. A distended bladder can change the angle between the cervix and uterus, potentially creating a straighter route for the catheter. It may also improve the visibility of the uterus during ultrasound-guided transfer. However, the same pressure can be uncomfortable, and the review found no convincing evidence that bladder filling increases the likelihood of pregnancy or live birth.

Another preparation method involves removing cervical mucus before the catheter is inserted. Mucus can theoretically obstruct the catheter, interfere with embryo placement, or make it harder for clinicians to see the tip of the device during ultrasound. Removing it may therefore appear technically helpful. Yet if the cervix is manipulated too roughly, the procedure can cause minor bleeding. Blood or mechanical irritation could theoretically affect the uterine environment, although the studies included in the review did not provide dependable evidence that mucus removal either improves or worsens reproductive outcomes.

The third technique, known as afterloading, changes when and how the embryo is introduced into the transfer catheter. In some versions of the procedure, the catheter is positioned first and the embryo is loaded or advanced afterward, with the aim of reducing the time the embryo spends in the device or improving control over its final placement. These technical differences may sound minor, but embryo transfer involves extremely small distances and delicate handling. Even so, the review found no robust evidence that afterloading leads to higher pregnancy or live-birth rates than conventional transfer procedures.

The researchers rated the certainty of evidence as low or very low across the comparisons. Many of the trials were small, and several had important methodological limitations, including inadequate reporting, possible selection bias, and insufficient information about complications. Small studies can produce apparently positive or negative results simply by chance, while differences in clinician experience, catheter type, ultrasound use, embryo stage, and patient characteristics can make results difficult to compare. As a result, a finding that appears promising in one fertility clinic may not be reproducible elsewhere.

The review also highlights how strongly local custom continues to influence IVF practice. Some clinics routinely require patients to drink water before transfer, while others allow a comfortably filled or empty bladder. Some remove cervical mucus as a standard step; others avoid doing so unless there is an obvious obstruction. These differences are often based on clinician preference, training, or historical protocol rather than high-quality comparative evidence. According to the review authors, this represents a familiar pattern in medicine: procedures can persist because they seem biologically plausible and are inexpensive, even when their clinical value has not been established.

There was limited information about side effects, but the techniques were not associated with clear evidence of serious harm. Full-bladder preparation is generally considered safe, although it can cause discomfort and may be particularly difficult for patients undergoing lengthy procedures or repeated treatment cycles. Mucus removal is usually quick, but forceful contact with the cervix can lead to spotting or bleeding. The main concerns therefore appear to involve discomfort and procedural difficulty rather than major medical complications. Still, safety alone does not demonstrate effectiveness, and even low-risk interventions should be tested if they are routinely imposed on patients.

The review authors say that answering this question will require larger, better-designed randomized trials with standardized transfer protocols and clinically meaningful outcomes, including live birth rather than pregnancy alone. Such research is challenging because embryo transfers are highly dependent on the person performing the procedure, and patients and clinicians may be reluctant to risk valuable embryos in a trial. The studies reviewed were also conducted in high-income countries, limiting confidence that their findings apply to clinics with fewer resources. Because the techniques are simple and inexpensive, researchers argue that carefully standardized studies in resource-limited settings could be especially valuable. For now, the evidence suggests that preparation before embryo transfer remains an area where tradition has outpaced proof—and where seemingly small procedural choices may continue to attract attention until stronger trials provide a clear answer.

Subject of Research: People

Article Title: Techniques for preparation prior to embryo transfer

News Publication Date: 5-Aug-2026

Web References: https://doi.org/10.1002/14651858.CD007682.pub3

References: Cochrane Database of Systematic Reviews; DOI: 10.1002/14651858.CD007682.pub3

Keywords: in vitro fertilization, IVF, embryo transfer, pregnancy rates, embryo implantation, cervical mucus removal, full bladder preparation, afterloading, fertility treatment, reproductive medicine, Cochrane review, clinical trials, human reproduction